Tvardi Therapeutics, Inc. (NASDAQ:TVRD) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Tvardi Therapeutics, Inc. (NASDAQ:TVRD) have received a consensus recommendation of “Moderate Buy” from the eight ratings firms that are presently covering the stock, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation, three have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 12-month target price among brokers that have covered the stock in the last year is $39.80.

A number of research firms recently weighed in on TVRD. HC Wainwright started coverage on Tvardi Therapeutics in a research report on Monday, June 8th. They issued a “buy” rating and a $9.00 price target for the company. Wall Street Zen downgraded Tvardi Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, April 4th. BTIG Research reaffirmed a “buy” rating and set a $15.00 price objective on shares of Tvardi Therapeutics in a research note on Wednesday, April 1st. Finally, Weiss Ratings reiterated a “sell (e+)” rating on shares of Tvardi Therapeutics in a report on Friday, April 10th.

Institutional Investors Weigh In On Tvardi Therapeutics

Hedge funds have recently made changes to their positions in the company. American Financial Group Inc. acquired a new position in Tvardi Therapeutics in the 4th quarter worth approximately $962,000. Vestal Point Capital LP acquired a new stake in Tvardi Therapeutics during the 3rd quarter valued at $6,508,000. Geode Capital Management LLC purchased a new stake in shares of Tvardi Therapeutics in the second quarter valued at $2,617,000. Invesco Ltd. purchased a new stake in shares of Tvardi Therapeutics in the third quarter valued at $3,219,000. Finally, Renaissance Technologies LLC boosted its position in shares of Tvardi Therapeutics by 246.3% in the fourth quarter. Renaissance Technologies LLC now owns 104,500 shares of the company’s stock worth $449,000 after buying an additional 74,325 shares during the period. Hedge funds and other institutional investors own 44.66% of the company’s stock.

Tvardi Therapeutics Stock Performance

Shares of NASDAQ:TVRD opened at $2.02 on Friday. The company has a market capitalization of $18.95 million, a PE ratio of -0.65 and a beta of 0.39. The stock has a fifty day moving average of $3.07 and a 200-day moving average of $3.55. Tvardi Therapeutics has a one year low of $1.50 and a one year high of $43.65.

Tvardi Therapeutics (NASDAQ:TVRD) last issued its earnings results on Friday, May 8th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.08). As a group, research analysts forecast that Tvardi Therapeutics will post -2.39 EPS for the current fiscal year.

Tvardi Therapeutics Company Profile

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body’s peripheral nervous system and immune cells. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.